# Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

> **NCT01526928** · PHASE1,PHASE2 · TERMINATED · sponsor: **Clovis Oncology, Inc.** · enrollment: 612 (actual)

## Conditions studied

- Locally Advanced or Metastatic Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Rociletinib
- **DRUG:** Rociletinib
- **DRUG:** Rociletinib
- **DRUG:** Rociletinib
- **DRUG:** Rociletinib
- **DRUG:** Rociletinib

## Key facts

- **NCT ID:** NCT01526928
- **Lead sponsor:** Clovis Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03-27
- **Primary completion:** 2018-07-03
- **Final completion:** 2018-08-27
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2020-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01526928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01526928, "Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01526928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*